Key Points
- Claritev SVP William Mintz sold 8,431 shares at an average price of $34.24, generating $288,677.44. His remaining stake fell 10.59% to 71,195 shares.
- Claritev shares opened at $35.06, with a market capitalization of approximately $597.8 million and a 12-month trading range of $11.50 to $74.07.
- Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $42.83; institutional investors own 87.15% of the company.
Claritev (NYSE:CTEV - Get Free Report) SVP William Mintz sold 8,431 shares of Claritev stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $34.24, for a total transaction of $288,677.44. Following the completion of the sale, the senior vice president owned 71,195 shares of the company's stock, valued at $2,437,716.80. This trade represents a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Claritev Trading Up 0.3%
NYSE:CTEV opened at $35.06 on Thursday. Claritev has a twelve month low of $11.50 and a twelve month high of $74.07. The company has a market cap of $597.77 million, a PE ratio of -2.06 and a beta of 0.74. The company's 50 day moving average is $29.32 and its two-hundred day moving average is $23.86.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Claritev from $22.00 to $30.00 and gave the company an "equal weight" rating in a report on Wednesday. Piper Sandler restated an "overweight" rating and issued a $73.00 target price on shares of Claritev in a research note on Wednesday. Citigroup reaffirmed a "buy" rating and set a $45.00 price target (up from $40.00) on shares of Claritev in a research report on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Claritev in a research note on Wednesday, June 24th. Finally, Wall Street Zen upgraded Claritev from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Claritev currently has a consensus rating of "Hold" and an average price target of $42.83.
View Our Latest Stock Analysis on Claritev
Institutional Investors Weigh In On Claritev
Hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming purchased a new position in shares of Claritev during the 4th quarter valued at approximately $25,000. Public Employees Retirement System of Ohio purchased a new stake in Claritev during the first quarter worth $38,000. Ameritas Investment Partners Inc. purchased a new stake in Claritev during the third quarter worth $42,000. Legal & General Group Plc acquired a new stake in Claritev during the third quarter valued at $45,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Claritev during the fourth quarter valued at $45,000. Institutional investors and hedge funds own 87.15% of the company's stock.
About Claritev
(
Get Free Report)
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
